Multidrug resistance in glioblastoma stem-like cells: Role of the hypoxic microenvironment and adenosine signaling

Molecular Aspects of Medicine

Volumn 55, Issue , 2017, Pages 140-151

  Uribe, Daniel ^a   Torres, Ángelo ^a   Rocha, José Dellis ^a   Niechi, Ignacio ^a   Oyarzún, Carlos ^a   Sobrevia, Luis ^b,c,d   San Martín, Rody ^a   Quezada, Claudia ^a  

^a UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c UNIVERSITY OF SEVILLE   (Spain)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Adenosine; ATP Binding Cassette (ABC) transporter; Glioblastoma multiforme; Glioblastoma stem like cells; Hypoxia; Multiple Drug Resistance

Indexed keywords

ABC TRANSPORTER; ADENOSINE; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; HERMES ANTIGEN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; VIMENTIN;

BRAIN HYPOXIA; CANCER GRADING; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL HETEROGENEITY; CELL PROLIFERATION; GLIOBLASTOMA; HUMAN; INTRACELLULAR SIGNALING; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PURINE METABOLISM; REVIEW; STEM CELL NICHE; TUMOR MICROENVIRONMENT; UPREGULATION; CELL HYPOXIA; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ADENOSINE; ATP-BINDING CASSETTE TRANSPORTERS; CELL HYPOXIA; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HUMANS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 85013379897     PISSN: 00982997     EISSN: 18729452     Source Type: Journal    
DOI: 10.1016/j.mam.2017.01.009     Document Type: Review

References (142)

1. Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., Clarke, M.F., Prospective identification of tumourigenic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 100:7 (2003), 3983–3988.
2. Arfuso, G.B., Millward, F., Dharmarajan, M., Warrier, S., Secreted frizzled-related protein 4 inhibits glioma stem-like cells by reversing epithelial to mesenchymal transition, inducing apoptosis and decreasing cancer stem cell properties. PLoS One, 10(6), 2015, e0127517.
3. Bao, S., Wu, Q., McLendon, R.E., Hao, Y., Shi, Q., Hjelmeland, A.B., Dewhirst, M.W., Bigner, D.D., Rich, J.N., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:7120 (2006), 756–760.
4. Bar, E.E., Glioblastoma, cancer stem cells and hypoxia. Brain Pathol. 21:2 (2011), 119–129.
5. Bavaresco, L., Bernardi, A., Braganhol, E., Cappellari, A.R., Rockenbach, L., Farias, P.F., Wink, M.R., Delgado-Cañedo, A., Battastini, A.M., The role of ecto-5′-nucleotidase/CD73 in glioma cell line proliferation. Mol. Cell. Biochem. 319:1–2 (2008), 61–68.
6. Beier, D., Hau, P., Proescholdt, M., Lohmeier, A., Wischhusen, J., Oefner, P.J., Aigner, L., Brawanski, A., Bogdahn, U., Beier, C.P., CD133+ and CD133− glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 67:9 (2007), 4010–4015.
7. Beier, D., Schulz, J.B., Beier, C.P., Chemoresistance of glioblastoma cancer stem cells - much more complex than expected. Mol. Cancer, 10, 2011, 128.
8. Becker, C.M., Oberoi, R.K., McFarren, S.J., Muldoon, D.M., Pafundi, D.H., Pokorny, J.L., Brinkmann, D.H., Ohlfest, J.R., Sarkaria, J.N., Largaespada, D.A., Elmquist, W.F., Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma. Neuro-Oncology 17:9 (2015), 1210–1219.
9. 2) localizes to the nucleus in glioblastoma multiforme cells. Xenobiotica 42:8 (2012), 748–755.
10. Bhowmik, A., Khan, R., Ghosh, M.K., Blood brain barrier: a challenge for effectual therapy of brain tumours. Biomed. Res. Int., 2015, 2015, 320941.
11. Bi, C.L., Fang, J.S., Chen, F.H., Wang, Y.J., Wu, J., Chemoresistance of CD133 (+) tumour stem cells from human brain glioma. Zhong nan da xue xue bao. Yi xue ban. J. Cent. South Univ. Med. Sci. 32:4 (2007), 568–573.
12. Blough, M.D., Westgate, M.R., Beauchamp, D., Kelly, J.J., Stechishin, O., Ramirez, A.L., Weiss, S., Cairncross, J.G., Sensitivity to temozolomide in brain tumour initiating cells. Neuro Oncol. 12:7 (2010), 756–760.
13. Bonnet, D., Dick, J.E., Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3 (1997), 730–737.
14. Bristow, R.G., Hill, R.P., Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat. Rev. Cancer 8:3 (2008), 180–192.
15. Bronger, H., König, J., Kopplow, K., Steiner, H.H., Ahmadi, R., Herold-Mende, C., Keppler, D., Nies, A.T., ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumour barrier. Cancer Res. 65:24 (2005), 11419–11428.
16. Brown, D.V., Daniel, P.M., D'Abaco, G.M., Gogos, A., Ng, W., Morokoff, A.P., Mantamadiotis, T., Coexpression analysis of CD133 and CD44 identifies Proneural and Mesenchymal subtypes of glioblastoma multiforme. Oncotarget 6:8 (2015), 6267–6280.
17. Calabrese, C., Poppleton, H., Kocak, M., Hogg, T.L., Fuller, C., Hamner, B., Oh, E.Y., Gaber, M.W., Finklestein, D., Allen, M., Frank, A., Bayazitov, I.T., Zakharenko, S.S., Gajjar, A., Davidoff, A., Gilbertson, R.J., A perivascular niche for brain tumour stem cells. Cancer Cell. 11:1 (2007), 69–82.
18. Calatozzolo, C., Gelati, M., Ciusani, E., Sciacca, F.L., Pollo, B., Cajola, L., Marras, C., Silvani, A., Vitellaro-Zuccarello, L., Croci, D., Boiardi, A., Salmaggi, A., Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 AND GST-pi in human glioma. J. Neurooncol 74:2 (2005), 113–121.
19. Carlsson, S.K., Brothers, S.P., Wahlestedt, C., Emerging treatment strategies for glioblastoma multiforme. EMBO Mol. Med. 6:11 (2014), 1359–1370.
20. Castillo, C.A., León, D., Ruiz, M.A., Albasanz, J.L., Martín, M., J. Neurochem. 105:6 (2008), 2315–2329.
21. Chandran, U.R., Luthra, S., Santana-Santos, L., Mao, P., Kim, S.H., Minata, M., Li, J., Benos, P.V., DeWang, M., Hu, B., Cheng, S.Y., Nakano, I., Sobol, R.W., Gene expression profiling distinguishes proneural glioma stem cells from mesenchymal glioma stem cells. Genom. Data 5 (2015), 333–336.
22. Chen, J., Li, Y., Yu, T.S., McKay, R.M., Burns, D.K., Kernie, S.G., Parada, L.F., A restricted cell population propagates glioblastoma growth following chemotherapy. Nature 488:7412 (2012), 522–526.
23. Chen, L., Feng, P., Li, S., Long, D., Cheng, J., Lu, Y., Zhou, D., Effect of hypoxia-inducible factor-1α silencing on the sensitivity of human brain glioma cells to doxorubicin and etoposide. Neurochem. Res. 34:5 (2009), 984–990.
24. Chen, W., Dong, J., Haiech, J., Kilhoffer, M.C., Zeniou, M., Cancer stem cell quiescence and plasticity as major challenges in cancer therapy. Stem Cells Int., 2016, 2016, 1740936.
25. Chen, Z., Shi, T., Zhang, L., Zhu, P., Deng, M., Huang, C., Hu, T., Jiang, L., Li, J., Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade. Cancer Lett. 370:1 (2016), 153–164.
26. Chou, C.W., Wang, C.C., Wu, C.P., Lin, Y.J., Lee, Y.C., Cheng, Y.W., Hsieh, C.H., Tumour cycling hypoxia induces chemoresistance in glioblastoma multiforme by upregulating the expression and function of ABCB1. Neuro Oncol. 14:10 (2012), 1227–1238.
27. Clement, V., Sanchez, P., de Tribolet, N., Radovanovic, I., Altaba, A.R., HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal and tumorigenicity. Curr. Biol. 17:2 (2007), 165–172.
28. Daniele, S., Zappelli, E., Natali, L., Martini, C., Trincavelli, M.L., Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy. Cell Death Dis., 5(11), 2014, e1539.
29. de Faria, G.P., de Oliveira, J.A., de Oliveira, J.G., Romano Sde, O., Neto, V.M., Maia, R.C., Differences in the expression pattern of P-glycoprotein and MRP1 in low-grade and high-grade gliomas. Cancer Invest 26:9 (2008), 883–889.
30. Dewhirst, M.W., Kimura, H., Rehmus, S.W., Braun, R.D., Papahadjopoulos, D., Hong, K., Secomb, T.W., Microvascular studies on the origins of perfusion-limited hypoxia. Br. J. Cancer Suppl. 27 (1996), S247–S251.
31. Evans, S.M., Jenkins, K.W., Jenkins, W.T., Dilling, T., Judy, K.D., Schrlau, A., Judkins, A., Hahn, S.M., Koch, C.J., Imaging and analytical methods as applied to the evaluation of vasculature and hypoxia in human brain tumours. Radiat. Res. 170:6 (2008), 677–690.
32. Evans, S.M., Judy, K.D., Dunphy, I., Jenkins, W.T., Hwang, W.T., Nelson, P.T., Lustig, R.A., Jenkins, K., Magarelli, D.P., Hahn, S.M., Collins, R.A., Grady, M.S., Koch, C.J., Hypoxia is important in the biology and aggression of human glial brain tumours. Clin. Cancer Res. 10:24 (2004), 8177–8184.
33. Evans, S.M., Judy, K.D., Dunphy, I., Jenkins, W.T., Nelson, P.T., Collins, R., Wileyto, E.P., Jenkins, K., Hahn, S.M., Stevens, C.W., Judkins, A.R., Phillips, P., Geoerger, B., Koch, C.J., Comparative measurements of hypoxia in human brain tumours using needle electrodes and EF5 binding. Cancer Res. 64:5 (2004), 1886–1892.
34. Ezashi, T., Das, P., Roberts, R.M., Low O2 tensions and the prevention of differentiation of hES cells. Proc. Natl. Acad. Sci. U. S. A. 102:13 (2005), 4783–4788.
35. Fredholm, B.B., Adenosine receptors as drug targets. Exp. Cell Res. 316:8 (2010), 1284–1288.
36. Fredholm, B.B., IJzerman, A.P., Jacobson, K.A., Klotz, K.N., Linden, J., International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53:4 (2001), 527–552.
37. Galli, R., Binda, E., Orfanelli, U., Cipelletti, B., Gritti, A., De Vitis, S., Fiocco, R., Foroni, C., Dimeco, F., Vescovi, A., Isolation and characterization of tumourigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64:19 (2004), 7011–7021.
38. Garrido, W., Rocha, J.D., Jaramillo, C., Fernandez, K., Oyarzun, C., San Martin, R., Quezada, C., Chemoresistance in high-grade gliomas: relevance of adenosine signalling in stem-like cells of glioblastoma multiforme. Curr. Drug Targets 15:10 (2014), 931–942.
39. Ghiringhelli, F., Bruchard, M., Chalmin, F., Rébé, C., Production of adenosine by ectonucleotidases: a key factor in tumour immunoescape. J. Biomed. Biotechnol., 2012, 2012, 473712.
40. Gong, W., Wang, Z., Wan, Y., Shi, L., Zhou, Y., Downregulation of ABCG2/BCRP protein inhibits migration and invasion in U251 glioma stem cells. Neuroreport 25:8 (2014), 625–632.
41. Günther, H.S., Schmidt, N.O., Phillips, H.S., Kemming, D., Kharbanda, S., Soriano, R., Modrusan, Z., Meissner, H., Westphal, M., Lamszus, K., Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 27:20 (2008), 2897–2909.
42. Heddleston, J.M., Wu, Q., Rivera, M., Minhas, S., Lathia, J.D., Sloan, A.E., Iliopoulos, O., Hjelmeland, A.B., Rich, J.N., Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumourigenic potential. Cell Death Differ. 19:3 (2012), 428–439.
43. Hemmati, H.D., Nakano, I., Lazareff, J.A., Masterman-Smith, M., Geschwind, D.H., Bronner-Fraser, M., Kornblum, H.I., Cancerous stem cells can arise from pediatric brain tumours. Proc. Natl. Acad. Sci. U. S. A. 100:25 (2003), 15178–15183.
44. Hinz, S., Lacher, S.K., Seibt, B.F., Müller, C.E., BAY60-6583 acts as a partial agonist at adenosine A2B receptors. J. Pharmacol. Exp. Ther. 349:3 (2014), 427–436.
45. Hirschmann-Jax, C., Foster, A.E., Wulf, G.G., Nuchtern, J.G., Jax, T.W., Gobel, U., Goodell, M.A., Brenner, M.K., A distinct “side population” of cells with high drug efflux capacity in human tumour cells. Proc. Natl. Acad. Sci. U. S. A. 101:39 (2004), 14228–14233.
46. Holmquist-Mengelbier, L., Fredlund, E., Lofstedt, T., Noguera, R., Navarro, S., Nilsson, H., Pietras, A., Vallon-Christersson, J., Borg, A., Gradin, K., Poellinger, L., Påhlman, S., Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell. 10:5 (2006), 413–423.
47. Hosokawa, Y., Takahashi, H., Inoue, A., Kawabe, Y., Funahashi, Y., Kameda, K., Sugimoto, K., Yano, H., Harada, H., Kohno, S., Ohue, S., Ohnishi, T., Tanaka, J., Oct-3/4 modulates the drug-resistant phenotype of glioblastoma cells through expression of ATP binding cassette transporter G2. Biochim. Biophys. Acta 1850:6 (2015), 1197–1205.
48. Hsieh, C.H., Lin, Y.J., Wu, C.P., Lee, H.T., Shyu, W.C., Wang, C.C., Livin contributes to tumour hypoxia-induced resistance to cytotoxic therapies in glioblastoma multiforme. Clin. Cancer Res. 21:2 (2015), 460–470.
49. Huang, L.E., Gu, J., Schau, M., Bunn, H.F., Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U. S. A. 95:14 (1998), 7987–7992.
50. Huang, W.J., Chen, W.W., Zhang, X., Glioblastoma multiforme: effect of hypoxia and hypoxia inducible factors on therapeutic approaches. Oncol. Lett. 12:4 (2016), 2283–2288.
51. Huang, Y.Y., Vecchio, D., Avci, P., Yin, R., Garcia-Diaz, M., Hamblin, M.R., Melanoma resistance to photodynamic therapy: new insights. Biol. Chem. 394:2 (2013), 239–250.
52. Huang, Z., Cheng, L., Guryanova, O.A., Wu, Q., Bao, S., Cancer stem cells in glioblastoma–molecular signaling and therapeutic targeting. Protein Cell. 1:7 (2010), 638–655.
53. Hume, W.J., Keratinocyte proliferative hierarchies confer protective mechanisms in surface epithelia. Br. J. Dermatol 112 (1985), 493–502.
54. Jain, R.K., di Tomaso, E., Duda, D.G., Loeffler, J.S., Sorensen, A.G., Batchelor, T.T., Angiogenesis in brain tumours. Nat. Rev. Neurosci. 8:8 (2007), 610–622.
55. Jensen, R.L., Brain tumour hypoxia: tumourigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J. Neurooncol 92:3 (2009), 317–335.
56. Jiang, P., Mukthavavam, R., Chao, Y., Bharati, I.S., Fogal, V., Pastorino, S., Cong, X., Nomura, N., Gallagher, M., Abbasi, T., Vali, S., Pingle, S.C., Makale, M., Kesari, S., Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs. J. Transl. Med., 12(1), 2014, 13.
57. Jin, F., Zhao, L., Guo, Y.J., Zhao, W.J., Zhang, H., Wang, H.T., Shao, T., Zhang, S.L., Wei, Y.J., Feng, J., Jiang, X.B., Zhao, H.Y., Influence of Etoposide on anti-apoptotic and multidrug resistance-associated protein genes in CD133 positive U251 glioblastoma stem-like cells. Brain Res. 1336 (2010), 103–111.
58. Jin, F., Zhao, L., Zhao, H.Y., Guo, S.G., Feng, J., Jiang, X.B., Zhang, S.L., Wei, Y.J., Fu, R., Zhao, J.S., Comparison between cells and cancer stem-like cells isolated from glioblastoma and astrocytoma on expression of anti-apoptotic and multidrug resistance–associated protein genes. Neuroscience 154:2 (2008), 541–550.
59. Jin, Y., Bin, Z.Q., Qiang, H., Liang, C., Hua, C., Jun, D., Dong, W.A., Qing, L., ABCG2/BCRP is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma. J. Cancer Res. Clin. Oncol. 135:10 (2009), 1369–1376.
60. Kallio, P.J., Wilson, W.J., O'Brien, S., Makino, Y., Poellinger, L., Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitin-proteasome pathway. J. Biol. Chem. 274:10 (1999), 6519–6525.
61. Keith, B., Johnson, R.S., Simon, M.C., HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 12:1 (2011), 9–22.
62. Kim, S.S., Seong, S., Lim, S.H., Kim, S.Y., Biliverdin reductase plays a crucial role in hypoxia-induced chemoresistance in human glioblastoma. Biochem. Biophys. Res. Commun. 440:4 (2013), 658–663.
63. Koh, M.Y., Darnay, B.G., Powis, G., Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation. Mol. Cell. Biol. 28:23 (2008), 7081–7095.
64. Koh, M.Y., Lemos, R., Liu, X., Powis, G., The hypoxia-associated factor switches cells from HIF-1α-to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumour growth and invasion. Cancer Res. 71:11 (2011), 4015–4027.
65. Kolenda, J., Jensen, S.S., Aaberg-Jessen, C., Christensen, K., Andersen, C., Brünner, N., Kristensen, B.W., Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids. J. Neurooncol 103:1 (2011), 43–58.
66. Kozovska, Z., Gabrisova, V., Kucerova, L., Colon cancer: cancer stem cells markers, drug resistance and treatment. Biomed. Pharmacother. 68:8 (2014), 911–916.
67. Kumar, V., Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?. Purinergic Signal 9:2 (2013), 145–165.
68. Kupp, R., Shtayer, L., Tien, A.C., Szeto, E., Sanai, N., Rowitch, D.H., Mehta, S., Lineage-restricted OLIG2-RTK signaling governs the molecular subtype of glioma stem-like cells. Cell Rep. 16:11 (2016), 2838–2845.
69. Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M.A., Dick, J.E., A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367:6464 (1994), 645–648.
70. Lathia, J.D., Gallagher, J., Heddleston, J.M., Wang, J., Eyler, C.E., MacSwords, J., Wu, Q., Vasanji, A., McLendon, R.E., Hjelmeland, A.B., Rich, J.N., Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell. 6:5 (2010), 421–432.
71. Ledoux, S., Runembert, I., Koumanov, K., Michel, J.B., Trugnan, G., Friedlander, G., Hypoxia enhances ecto-5′-nucleotidase activity and cell surface expression in endothelial cells role of membrane lipids. Circ. Res. 92:8 (2003), 848–855.
72. Lee, J., Kotliarova, S., Kotliarov, Y., Li, A., Su, Q., Donin, N.M., Pastorino, S., Purow, B.W., Christopher, N., Zhang, W., Park, J.K., Fine, H.A., Tumour stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumours than do serum-cultured cell lines. Cancer Cell. 9:5 (2006), 391–403.
73. Li, P., Zhou, C., Xu, L., Xiao, H., Hypoxia enhances stemness of cancer stem cells in glioblastoma: an in vitro study. Int. J. Med. Sci. 10:4 (2013), 399–407.
74. Li, Z., Bao, S., Wu, Q., Wang, H., Eyler, C., Sathornsumetee, S., Shi, Q., Cao, Y., Lathia, J., McLendon, R.E., Hjelmeland, A.B., Rich, J.N., Hypoxia-inducible factors regulate tumourigenic capacity of glioma stem cells. Cancer Cell. 15:6 (2009), 501–513.
75. Liang, S.C., Yang, C.Y., Tseng, J.Y., Wang, H.L., Tung, C.Y., Liu, H.W., Chen, C.Y., Yeh, Y.C., Chou, T.Y., Yang, M.H., Whang-Peng, J., Lin, C.H., ABCG2 localizes to the nucleus and modulates CDH1Expression in lung cancer cells. Neoplasia 17:3 (2015), 265–278.
76. Ligon, K.L., Huillard, E., Mehta, S., Kesari, S., Liu, H., Alberta, J.A., Bachoo, R.M., Kane, M., Louis, D.N., Depinho, R.A., Anderson, D.J., Stiles, C.D., Rowitch, D.H., Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron 53:4 (2007), 503–517.
77. Liu, G., Yuan, X., Zeng, Z., Tunici, P., Ng, H., Abdulkadir, I.R., Lu, L., Irvin, D., Black, K.L., Yu, J.S., Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer, 5(1), 2006, 67.
78. Liu, T.Z., Wang, X., Bai, Y.F., Liao, H.Z., Qiu, S.C., Yang, Y.Q., Yan, X.H., Chen, J., Guo, H.B., Zhang, S.Z., The HIF-2alpha dependent induction of PAP and adenosine synthesis regulates glioblastoma stem cell function through the A2B adenosine receptor. Int. J. Biochem. Cell. Biol. 49 (2014), 8–16.
79. Liu, Y., Guo, Q., Zhang, H., Li, G.H., Feng, S., Yu, X.Z., Kong, L.S., Zhao, L., Jin, F., Effect of siRNA-Livin on drug resistance to chemotherapy in glioma U251 cells and CD133+ stem cells. Exp. Ther. Med. 10:4 (2015), 1317–1323.
80. Lottaz, C., Beier, D., Meyer, K., Kumar, P., Hermann, A., Schwarz, J., Junker, M., Oefner, P.J., Bogdahn, U., Wischhusen, J., Spang, R., Storch, A., Beier, C.P., Transcriptional profiles of CD133+ and CD133− glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res. 70:5 (2010), 2030–2040.
81. Mao, P., Joshi, K., Li, J., Kim, S.H., Li, P., Santana-Santos, L., Luthra, S., Chandran, U.R., Benos, P.V., Smith, L., Wang, M., Hu, B., Cheng, S.Y., Sobol, R.W., Nakano, I., Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc. Natl. Acad. Sci. USA. 2013 110:21 (2013), 8644–8649.
82. Marín-Hernández, A., Gallardo-Pérez, J.C., Ralph, S.J., Rodríguez-Enríquez, S., Moreno-Sánchez, R., HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev. Med. Chem. 9:9 (2009), 1084–1101.
83. Martín, V., Sanchez-Sanchez, A.M., Herrera, F., Gomez-Manzano, C., Fueyo, J., Alvarez-Vega, M.A., Antolin, I., Rodriguez, C., Melatonin-induced methylation of the ABCG2/BCRP/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells. Br. J. Cancer 108:10 (2013), 2005–2012.
84. Matsumoto, Y., Tamiya, T., Nagao, S., Resistance to topoisomerase II inhibitors in human glioma cell lines overexpressing multidrug resistant associated protein (MRP) 2. J. Med. Invest 52:1–2 (2005), 41–48.
85. McCord, A.M., Jamal, M., UShankavaram, U.T., Lang, F.F., Camphausen, K., Tofilon, P.J., Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol. Cancer Res. 7:4 (2009), 489–497.
86. Merighi, S., Benini, A., Mirandola, P., Gessi, S., Varani, K., Leung, E., Maclennan, S., Baraldi, P.G., Borea, P.A., Hypoxia inhibits paclitaxel-induced apoptosis through adenosine-mediated phosphorylation of bad in glioblastoma cells. Mol. pharmacol 72:1 (2007), 162–172.
87. Merighi, S., Benini, A., Mirandola, P., Gessi, S., Varani, K., Leung, E., Maclennan, S., Borea, P.A., Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells. Biochem. Pharmacol. 72:1 (2006), 19–31.
88. Moreno, M., Fernández, V., Monllau, J.M., Borrell, V., Lerin, C., de la Iglesia, N., Transcriptional profiling of hypoxic neural stem cells identifies calcineurin-NFATc4 signaling as a major regulator of neural stem cell biology. Stem Cell Rep. 5:2 (2015), 157–165.
89. Munoz, J.L., Walker, N.D., Scotto, K.W., Rameshwar, P., Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells. Cancer Lett. 367:1 (2015), 69–75.
90. Nardinocchi, L., Pantisano, V., Puca, R., Porru, M., Aiello, A., Grasselli, A., Leonetti, C., Safran, M., Rechavi, G., Givol, D., Farsetti, A., D'Orazi, G., Zinc downregulates HIF-1α and inhibits its activity in tumour cells in vitro and in vivo. PLoS One, 5(12), 2010, e15048.
91. Omuro, A., DeAngelis, L.M., Glioblastoma and other malignant gliomas: a clinical review. JAMA 310:17 (2013), 1842–1850.
92. Onishi, H., Yamasaki, A., Kawamoto, M., Imaizumi, A., Katano, M., Hypoxia but not normoxia promotes Smoothened transcription through upregulation of RBPJ and Mastermind-like 3 in pancreatic cancer. Cancer Lett. 371:2 (2016), 143–150.
93. Onishi, H., Kai, M., Odate, S., Iwasaki, H., Morifuji, Y., Ogino, T., Morisaki, T., Nakashima, Y., Katano, M., Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer. Cancer Sci. 102:6 (2011), 1144–1150.
94. Peigñan, L., Garrido, W., Segura, R., Melo, R., Rojas, D., Cárcamo, J.G., San Martín, R., Quezada, C., Combined use of anticancer drugs and an inhibitor of multiple drug resistance-associated protein-1 increases sensitivity and decreases survival of glioblastoma multiforme cells in vitro. Neurochem. Res. 36:8 (2011), 1397–1406.
95. Petrella, B.L., Lohi, J., Brinckerhoff, C.E., Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2a in von Hippel-Lindau renal cell carcinoma. Oncogene 24:6 (2005), 1043–1052.
96. Pettengill, M., Robson, S., Tresenriter, M., Millán, J.L., Usheva, A., Bingham, T., Belderbos, M., Bergelson, I., Burl, S., Kampmann, B., Gelinas, L., Kollmann, T., Bont, L., Levy, O., Soluble ecto-5′-nucleotidase (5′-NT), alkaline phosphatase, and adenosine deaminase (ADA1) activities in neonatal blood favor elevated extracellular adenosine. J. Biol. Chem. 288:38 (2013), 27315–27326.
97. Phillips, H.S., Kharbanda, S., Chen, R., Forrest, W.F., Soriano, R.H., Wu, T.D., Misra, A., Nigro, J.M., Colman, H., Soroceanu, L., Williams, P.M., Modrusan, Z., Feuerstein, B.G., Aldape, K., Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 9:3 (2006), 157–173.
98. Pistollato, F., Abbadi, S., Rampazzo, E., Persano, L., Della Puppa, A., Frasson, C., Sarto, E., Scienza, R., D'avella, D., Basso, G., Intratumoural hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem Cells 28:5 (2010), 851–862.
99. Qiang, L., Wu, T., Zhang, H.W., Lu, N., Hu, R., Wang, Y.J., Zhao, L., Chen, F.H., Wang, X.T., You, Q.D., Guo, Q.L., HIF-1α is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway. Cell Death Differ. 19:2 (2012), 284–294.
100. Quezada, C., Garrido, W., Oyarzún, C., Fernández, K., Segura, R., Melo, R., Casanello, P., Sobrevia, L., San Martín, R., 5′-ectonucleotidase mediates multiple-drug resistance in glioblastoma multiforme cells. J. Cell. Physiol. 228:3 (2013), 602–608.
101. Rampazzo, E., Persano, L., Pistollato, F., Moro, E., Frasson, C., Porazzi, P., Della Puppa, A., Bresolin, S., Battilana, G., Indraccolo, S., Te Kronnie, G., Argenton, F., Tiso, N., Basso, G., Wnt activation promotes neuronal differentiation of glioblastoma. Cell Death Dis., 4(2), 2013, e500.
102. Ricci-Vitiani, L., Lombardi, D.G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., De Maria, R., Identification and expansion of human colon-cancer-initiating cells. Nature 445:7123 (2007), 111–115.
103. Ricci-Vitiani, L., Pallini, R., Biffoni, M., Todaro, M., Invernici, G., Cenci, T., Maira, G., Parati, E.A., Stassi, G., Larocca, L.M., De Maria, R., Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468:7325 (2010), 824–828.
104. Robinson, C.M., Ohh, M., The multifaceted von Hippel-Lindau tumour suppressor protein. FEBS Lett. 588:16 (2014), 2704–2711.
105. Ropolo, M., Daga, A., Griffero, F., Foresta, M., Casartelli, G., Zunino, A., Poggi, A., Cappelli, E., Zona, G., Spaziante, R., Corte, G., Frosina, G., Comparative analysis of DNA repair in stem and nonstem glioma cell cultures. Mol. Cancer Res. 7:3 (2009), 383–392.
106. Sadej, R., Spychala, J., Skladanowski, A.C., Expression of ecto-5′-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma. Melanoma Res. 16:3 (2006), 213–222.
107. Saraswathy, M., Gong, S., Different strategies to overcome multidrug resistance in cancer. Biotechnol. Adv. 31:8 (2013), 1397–1407.
108. Sarkaria, J.N., Kitange, G.J., James, C.D., Plummer, R., Calvert, H., Weller, M., Wick, W., Mechanisms of chemoresistance in malignant glioma. Clin. Cancer Res. 14:10 (2008), 2900–2908.
109. Sathornsumetee, S., Cao, Y., Marcello, J.E., Herndon, J.E. 2nd, McLendon, R.E., Desjardins, A., Friedman, H.S., Dewhirst, M.W., Vredenburgh, J.J., Rich, J.N., Tumour angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J. Clin. Oncol. 26:2 (2008), 271–278.
110. Seidel, S., Garvalov, B.K., Wirta, V., von Stechow, L., Schanzer, A., Meletis, K., Wolter, M., Sommerlad, D., Henze, A.T., Nistér, M., Reifenberger, G., Lundeberg, J., Frisén, J., Acker, T., A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 133:Pt4 (2010), 983–995.
111. Semenza, G.L., Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29:5 (2010), 625–634.
112. Scharpfenecker, M., Kruse, J.J., Sprong, D., Russell, N.S., Ten Dijke, P., Stewart, F.A., Ionizing radiation shifts the PAI-1/ID-1 balance and activates notch signaling in endothelial cells. Int. J. Radiat. Oncol. Biol. Phys. 73:2 (2009), 506–513.
113. Shin, B., Burkhardt, J.K., Boockvar, J., Glioblastoma multiforme stem-like cells and hypoxia: the novel role of HAF. Neurosurgery, 69(4), 2011, N21.
114. Singh, S.K., Clarke, I.D., Terasaki, M., Bonn, V.E., Hawkins, C., Squire, J., Dirks, P.B., Identification of a cancer stem cell in human brain tumours. Cancer Res. 63 (2003), 5821–5828.
115. Singh, S.K., Hawkins, C., Clarke, I.D., Squire, J.A., Bayani, J., Hide, T., Henkelman, R.M., Cusimano, M.D., Dirks, P.B., Identification of human brain tumour initiating cells. Nature 432:7015 (2004), 396–401.
116. Soeda, A., Park, M., Lee, D., Mintz, A., Androutsellis-Theotokis, A., McKay, R.D., Engh, J., Iwama, T., Kunisada, T., Kassam, A.B., Pollack, I.F., Park, D.M., Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 28:45 (2009), 3949–3959.
117. Son, M.J., Woolard, K., Nam, D.H., Lee, J., Fine, H.A., SSEA-1 is an enrichment marker for tumour-initiating cells in human glioblastoma. Cell Stem Cell. 4:5 (2009), 440–452.
118. Sørensen, M.D., Fosmark, S., Hellwege, S., Beier, D., Kristensen, B.W., Beier, C.P., Chemoresistance and chemotherapy targeting stem-like cells in malignant glioma. Adv. Exp. Med. Biol. 853 (2015), 111–138.
119. Spychala, J., Lazarowski, E., Ostapkowicz, A., Ayscue, L.H., Jin, A., Mitchell, B.S., Role of estrogen receptor in the regulation of ecto-5′-nucleotidase and adenosine in breast cancer. Clin. Cancer Res. 10:2 (2004), 708–717.
120. Stagg, J., Smyth, M.J., Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 29:39 (2010), 5346–5358.
121. Stupp, R., Mason, W.P., Van Den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J., Belanger, K., Brandes, A.A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R.C., Ludwin, S.K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J.G., Eisenhauer, E., Mirimanoff, R.O., European organisation for research and treatment of cancer brain tumour and radiotherapy groups, national cancer institute of Canada clinical trials group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352:10 (2005), 987–996.
122. Suvà, M.L., Rheinbay, E., Gillespie, S.M., Patel, A.P., Wakimoto, H., Rabkin, S.D., Riggi, N., Chi, A.S., Cahill, D.P., Nahed, B.V., Curry, W.T., Martuza, R.L., Rivera, M.N., Rossetti, N., Kasif, S., Beik, S., Kadri, S., Tirosh, I., Wortman, I., Shalek, A.K., Rozenblatt-Rosen, O., Regev, A., Louis, D.N., Bernstein, B.E., Reconstructing and reprogramming the tumour-propagating potential of glioblastoma stem-like cells. Cell 157:3 (2014), 580–594.
123. Synnestvedt, K., Furuta, G.T., Comerford, K.M., Louis, N., Karhausen, J., Eltzschig, H.K., Hansen, K.R., Thompson, L.F., Colgan, S.P., Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J. Clin. Invest 110:7 (2002), 993–1002.
124. Torres, A., Vargas, Y., Uribe, D., Jaramillo, C., Gleisner, A., Salazar-Onfray, F., López, M.N., Melo, R., Oyarzún, C., Martín, R.S., Quezada, C., Adenosine A3 receptor elicits chemoresistance mediated by multiple resistance-associated protein-1 in human glioblastoma stem-like cells. Oncotarget 7:41 (2016), 67373–67386.
125. Trotter, M.J., Chaplin, D.J., Durand, R.E., Olive, P.L., The use of fluorescent probes to identify regions of transient perfusion in murine tumours. Int. J. Radiat. Oncol. Biol. Phys. 16:4 (1989), 931–934.
126. Tunici, P., Bissola, L., Lualdi, E., Pollo, B., Cajola, L., Broggi, G., Sozzi, G., Finocchiaro, G., Genetic alterations and in vivo tumourigenicity of neurospheres derived from an adult glioblastoma. Mol. Cancer, 3(1), 2004, 25.
127. Vaupel, P., Kallinowski, F., Okunieff, P., Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumours: a review. Cancer Res. 49:23 (1989), 6449–6465.
128. Vaupel, P., Mayer, A., Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 26:2 (2007), 225–239.
129. Verhaak, R.G.W., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D., Miller, C.R., Ding, L., Golub, T., Mesirov, J.P., Alexe, G., Lawrence, M., O'Kelly, M., Tamayo, P., Weir, B.A., Stacey, Gabrie, Winckler, W., Gupta, S., Jakkula, L., Feiler, H.J., Hodgson, G., James, C.D., Sarkaria, J.N., Brennan, C., Kahn, A., Spellman, P.T., Wilson, R.K., Speed, T.P., Gray, J.W., Meyerson, M., Getz, G., Perou, C.M., Hayes, D.N., The Cancer Genome Atlas Research Network. An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell., 17(1), 2010, 98.
130. Wang, L., Zhou, X., Zhou, T., Ma, D., Chen, S., Zhi, X., Yin, L., Shao, Z., Ou, Z., Zhou, P., Ecto-5′-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J. Cancer Res. Clin. Oncol. 134:3 (2008), 365–372.
131. Wang, R., Sheps, J.A., Ling, V., ABC transporters, bile acids, and inflammatory stress in liver cancer. Curr. Pharm. Biotechnol. 12:4 (2011), 636–646.
132. Ween, M.P., Armstrong, M.A., Oehler, M.K., Ricciardelli, C., The role of ABC transporters in ovarian cancer progression and chemoresistance. Crit. Rev. Oncol. Hematol. 96:2 (2015), 220–256.
133. Weller, M., Stupp, R., Reifenberger, G., Brandes, A.A., van den Bent, M.J., Wick, W., Hegi, M.E., MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. Nat. Rev. Neurol. 6:1 (2010), 39–51.
134. Wen, P.Y., Kesari, S., Malignant gliomas in adults. N. Engl. J. Med. 359:5 (2008), 492–507.
135. Wilkens, S., Structure and mechanism of ABC transporters. F1000Prime Rep., 7, 2015, 14.
136. Wong, S.T., Goodin, S., Overcoming drug resistance in patients with metastatic breast cancer. Pharmacotherapy 29:8 (2009), 954–965.
137. Wu, Q., Yang, Z., Nie, Y., Shi, Y., Fan, D., Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches. Cancer Lett. 347:2 (2014), 159–166.
138. Xie, Y., Bergström, T., Jiang, Y., Johansson, P., Marinescu, V.D., Lindberg, N., Segerman, A., Wicher, G., Niklasson, M., Baskaran, S., Sreedharan, S., Everlien, I., Kastemar, M., Hermansson, A., Elfineh, L., Libard, S., Holland, E.C., Hesselager, G., Alafuzoff, I., Westermark, B., Nelander, S., Forsberg-Nilsson, K., Uhrbom, L., The human glioblastoma cell culture resource: validated cell models representing all molecular subtypes. EBioMedicine 2:10 (2015), 1351–1363.
139. Yan, G.N., Yang, L., Lv, Y.F., Shi, Y., Shen, L.L., Yao, X.H., Guo, Q.N., Zhang, P., Cui, Y.H., Zhang, X., Bian, X.W., Guo, D.Y., Endothelial cells promote stem-like phenotype of glioma cells through activating the Hedgehog pathway. J. Pathol. 234:1 (2014), 11–22.
140. Zhang, K., Wang, X.Q., Zhou, B., Zhang, L., The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis. Fam. Cancer 12:3 (2013), 449–458.
141. Zhang, Y., Wang, S.X., Ma, J.W., Li, H.Y., Ye, J.C., Xie, S.M., Du, B., Zhong, X.Y., EGCG inhibits properties of glioma stem-like cells and synergizes with temozolomide through downregulation of P-glycoprotein inhibition. J. Neurooncol 121:1 (2015), 41–52.
142. Zhu, T.S., Costello, M.A., Talsma, C.E., Flack, C.G., Crowley, J.G., Hamm, L.L., He, X., Hervey-Jumper, S.L., Heth, J.A., Muraszko, K.M., DiMeco, F., Vescovi, A.L., Fan, X., Endothelial cells create a stem cell niche in glioblastoma by providing Notch ligands that nurture self-renewal of cancer stem-like cells. Cancer Res. 71:18 (2011), 6061–6072.